| scholarly article | Q13442814 |
| P50 | author | William C Huang | Q37368983 |
| Alan J Wein | Q67190115 | ||
| Rosemarie Mick | Q107311719 | ||
| P2093 | author name string | S Bruce Malkowicz | |
| Keith N Van Arsdalen | |||
| Ricardo F Sánchez-Ortiz | |||
| P433 | issue | 1 | |
| P921 | main subject | bladder carcinoma | Q18556149 |
| P304 | page(s) | 110-5; discussion 115 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Journal of Urology | Q15709979 |
| P1476 | title | An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma | |
| P478 | volume | 169 |
| Q36710334 | An analysis of preoperative delays prior to radical cystectomy for bladder cancer in Quebec |
| Q35671292 | Biomarkers for prognosis and treatment selection in advanced bladder cancer patients |
| Q34479053 | Bladder cancer in the elderly |
| Q57452829 | CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer |
| Q35576964 | Care transitions between hospitals are associated with treatment delay for patients with muscle invasive bladder cancer |
| Q84173659 | Clinical trials: nationally representative data in urology |
| Q95637487 | Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic |
| Q61808638 | Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer |
| Q39177293 | Contemporary update on neoadjuvant therapy for bladder cancer |
| Q51150690 | Do blood groups have effect on prognosis of patients undergoing radical cystectomy? |
| Q63966630 | Factors affecting choice between ureterostomy, ileal conduit and continent reservoir after radical cystectomy: Japanese series |
| Q34660254 | Gender disparities in hematuria evaluation and bladder cancer diagnosis: a population based analysis |
| Q36224399 | High-Dose Viscum album Extract Treatment in the Prevention of Recurrent Bladder Cancer: A Retrospective Case Series |
| Q35731224 | Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma |
| Q37153419 | Impact of treatment delay in patients with bladder cancer managed with partial cystectomy in Quebec: a population-based study |
| Q36606956 | Improving outcomes with radical cystectomy for high-grade invasive bladder cancer |
| Q39413207 | Landmarks in the treatment of muscle-invasive bladder cancer |
| Q36749513 | Lunar phases and zodiac signs do not influence quality of radical cystectomy--a statistical analysis of 452 patients with invasive bladder cancer |
| Q41706346 | Lymph node density in muscle-invasive transitional cell carcinoma of the urinary bladder; De novo versus progressive disease |
| Q37125906 | Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. |
| Q37375315 | Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings |
| Q79370791 | Neoadjuvant chemotherapy for bladder cancer |
| Q88886395 | Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma |
| Q37472550 | Perioperative chemotherapy for muscle-invasive bladder cancer. |
| Q41264196 | Perioperative chemotherapy: the case for adjuvant chemotherapy for muscle-invasive bladder cancer |
| Q37559717 | Predictive value of clinicopathological markers for the metachronous bladder cancer and prognosis of upper tract urothelial carcinoma |
| Q41127920 | Preoperative anemia is associated with adverse outcome in patients with urothelial carcinoma of the bladder following radical cystectomy |
| Q36487460 | Prognostic impact of comorbidity in patients with bladder cancer |
| Q37197530 | Pros and cons of radical cystectomy in the treatment of T1G3 bladder cancer |
| Q46352975 | Quality of diagnostic staging in patients with bladder cancer: a process-outcomes link |
| Q46470892 | Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure |
| Q35125750 | Role of systemic peri-operative chemotherapy in management of transitional cell carcinoma of bladder |
| Q37564393 | Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation. |
| Q26774347 | Standard cystectomy fits all: truth or myth? |
| Q84042816 | The impact of delaying radical nephrectomy for stage II or higher renal cell carcinoma |
| Q35028256 | The time from diagnosis of bladder cancer to radical cystectomy in Polish urological centres - results of CysTiming Poland study |
| Q35533822 | Timing of radical cystectomy in Central Europe - multicenter study on factors influencing the time from diagnosis to radical treatment of bladder cancer patients |
| Q36171243 | Update on the management of invasive bladder cancer 2012. |
| Q34553950 | Upper tract urothelial carcinoma: Impact of time to surgery |
| Q37024885 | Urinary markers in screening patients with hematuria. |
| Q37944437 | Urothelial carcinoma of the bladder: definition, treatment and future efforts |
| Q33818844 | Variation in the intensity of hematuria evaluation: a target for primary care quality improvement |
| Q35622834 | Variations in reconstruction after radical cystectomy |
| Q86630666 | [Cystectomy in the elderly patient] |
| Q80079732 | [Standards and perspectives in diagnosis and therapy of bladder carcinoma] |
Search more.